Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology firm, is capturing the attention of investors with its notable potential upside of 57.33%, according to analyst ratings. With a market capitalization of $1.67 billion, this U.S.-based company is making strides in the healthcare sector, specifically focusing on developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology.

At the heart of Tyra Biosciences’ innovation is SNÅP, a state-of-the-art precision medicine platform. This technology is designed to advance drug development by providing molecular insights that predict genetic alterations. The company’s lead product candidate, TYRA-300, is currently in clinical trials for…